Clinical Trial Update: Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the optimal starting subcutaneous dose of Mircera for maintenance treatment of anemia in pediatric chronic kidney disease patients on or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia, Renal Insufficiency, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2022-03-07